Literature DB >> 33531640

The Angelina Jolie effect: Contralateral risk-reducing mastectomy trends in patients at increased risk of breast cancer.

Narendra Nath Basu1,2, James Hodson3, Shaunak Chatterjee3, Ashu Gandhi4, Julie Wisely4, James Harvey4, Lyndsey Highton4, John Murphy4, Nicola Barnes4, Richard Johnson4, Lester Barr4, Cliona C Kirwan4, Sacha Howell4,5, Andrew D Baildam4, Anthony Howell4,5, D Gareth Evans4,5,6,7,8.   

Abstract

Contralateral risk-reducing mastectomy (CRRM) rates have tripled over the last 2 decades. Reasons for this are multi-factorial, with those harbouring a pathogenic variant in the BRCA1/2 gene having the greatest survival benefit. On May 14th, 2013, Angelina Jolie shared the news of her bilateral risk-reducing mastectomy (BRRM), on the basis of her BRCA1 pathogenic variant status. We evaluated the impact of this news on rates of CRRM in women with increased risk for developing breast cancer after being diagnosed with unilateral breast cancer. The prospective cohort study included all women with at least a moderate lifetime risk of developing breast cancer who attended our family history clinic (1987-2019) and were subsequently diagnosed with unilateral breast cancer. Rates of CRRM were then compared between patients diagnosed with breast cancer before and after Angelina Jolie's announcement (pre- vs. post-AJ). Of 386 breast cancer patients, with a mean age at diagnosis of 48 ± 8 years, 268 (69.4%) were diagnosed in the pre-AJ period, and 118 (30.6%) in the post-AJ period. Of these, 123 (31.9%) underwent CRRM, a median 42 (interquartile range: 11-54) days after the index cancer surgery. Rates of CRRM doubled following AJ's news, from 23.9% pre-AJ to 50.0% post AJ (p < 0.001). Rates of CRRM were found to decrease with increasing age at breast cancer (p < 0.001) and tumour TNM stage (p = 0.040), and to increase with the estimated lifetime risk of breast cancer (p < 0.001) and tumour grade (p = 0.015) on univariable analysis. After adjusting for these factors, the step-change increase in CRRM rates post-AJ remained significant (odds ratio: 9.61, p < 0.001). The AJ effect appears to have been associated with higher rates of CRRM amongst breast cancer patients with increased cancer risk. CRRM rates were highest amongst younger women and those with the highest lifetime risk profile. Clinicians need to be aware of how media news can impact on the delivery of cancer related services. Communicating objective assessment of risk is important when counselling women on the merits of risk-reducing surgery.

Entities:  

Year:  2021        PMID: 33531640     DOI: 10.1038/s41598-021-82654-x

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  3 in total

1.  Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis.

Authors:  Bernadette A M Heemskerk-Gerritsen; Matti A Rookus; Cora M Aalfs; Margreet G E M Ausems; Johanna M Collée; Liesbeth Jansen; C Marleen Kets; Kristien B M I Keymeulen; Linetta B Koppert; Hanne E J Meijers-Heijboer; Thea M Mooij; Rob A E M Tollenaar; Hans F A Vasen; Maartje J Hooning; Caroline Seynaeve
Journal:  Int J Cancer       Date:  2014-07-08       Impact factor: 7.396

Review 2.  Risk-reducing mastectomy for the prevention of primary breast cancer.

Authors:  Nora E Carbine; Liz Lostumbo; Judi Wallace; Henry Ko
Journal:  Cochrane Database Syst Rev       Date:  2018-04-05

Review 3.  Contralateral risk-reducing mastectomy: review of risk factors and risk-reducing strategies.

Authors:  N N Basu; L Barr; G L Ross; D G Evans
Journal:  Int J Surg Oncol       Date:  2015-01-27
  3 in total
  4 in total

1.  PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients.

Authors:  Daniele Giardiello; Maartje J Hooning; Michael Hauptmann; Renske Keeman; B A M Heemskerk-Gerritsen; Heiko Becher; Carl Blomqvist; Stig E Bojesen; Manjeet K Bolla; Nicola J Camp; Kamila Czene; Peter Devilee; Diana M Eccles; Peter A Fasching; Jonine D Figueroa; Henrik Flyger; Montserrat García-Closas; Christopher A Haiman; Ute Hamann; John L Hopper; Anna Jakubowska; Floor E Leeuwen; Annika Lindblom; Jan Lubiński; Sara Margolin; Maria Elena Martinez; Heli Nevanlinna; Ines Nevelsteen; Saskia Pelders; Paul D P Pharoah; Sabine Siesling; Melissa C Southey; Annemieke H van der Hout; Liselotte P van Hest; Jenny Chang-Claude; Per Hall; Douglas F Easton; Ewout W Steyerberg; Marjanka K Schmidt
Journal:  Breast Cancer Res       Date:  2022-10-21       Impact factor: 8.408

2.  Nationwide Trends in Contralateral Prophylactic Mastectomies: An Analysis of 55,060 Unilateral Breast Cancer Patients.

Authors:  Mohammed S Shaheen; Arash Momeni
Journal:  Plast Reconstr Surg Glob Open       Date:  2022-05-25

3.  Social Media Listening to Understand the Lived Experience of Individuals in Europe With Metastatic Breast Cancer: A Systematic Search and Content Analysis Study.

Authors:  Manuelita Mazza; Maria Piperis; Sathyaraj Aasaithambi; Jyoti Chauhan; Alexandros Sagkriotis; Claudia Vieira
Journal:  Front Oncol       Date:  2022-05-20       Impact factor: 5.738

4.  Satisfaction and Quality of Life of Healthy and Unilateral Diseased BRCA1/2 Pathogenic Variant Carriers after Risk-Reducing Mastectomy and Reconstruction Using the BREAST-Q Questionnaire.

Authors:  Natalie Herold; Martin Hellmich; Frank Lichtenheldt; Beyhan Ataseven; Vanessa Hillebrand; Barbara Wappenschmidt; Rita Katharina Schmutzler; Kerstin Rhiem
Journal:  Genes (Basel)       Date:  2022-07-28       Impact factor: 4.141

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.